# Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)

> **NCT03704610** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 31 (actual)

## Conditions studied

- Extrathoracic Sarcoidosis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03704610
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2021-06-21
- **Final completion:** 2021-09-28
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03704610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03704610, "Efficacy of Remission-induction Regimen With Infliximab for Severe Extrathoracic Sarcoidosis (EFIRTES)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03704610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*